Showing 18,961 - 18,980 results of 24,159 for search '(( significant ((event decrease) OR (unit increase)) ) OR ( significant decrease decrease ))', query time: 0.49s Refine Results
  1. 18961

    Table 5_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

    Published 2025
    “…</p>Results<p>HFD induced biochemical abnormalities and liver injury, which were significantly reversed by Pac, as evidenced by decreased plasma levels of AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), TG (Triglyceride), and TC (Total cholesterol), and reduced hepatic TG and TC levels. …”
  2. 18962

    Raw data of the subsystem. by Jie Huang (104235)

    Published 2025
    “…Spatially, the CCD demonstrates a characteristic pattern of decreasing from east to west. Overall, achieving a “cross-level transition” in CCD is challenging, and the neighboring provinces significantly influence the enhancement of local CCD. …”
  3. 18963

    Table 1_Identification of two KPC variants, KPC-204 and KPC-227, in ST11-K64 Klebsiella pneumoniae during prolonged hospitalization of a single patient.docx by Shijun Sun (9287651)

    Published 2025
    “…Introduction<p>Carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a critical global public health challenge due to its significant association with morbidity and mortality. …”
  4. 18964
  5. 18965

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  6. 18966

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  7. 18967

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  8. 18968
  9. 18969

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  10. 18970
  11. 18971
  12. 18972

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  13. 18973

    Rht1 functions in cell cycle progression and modulates fluconazole susceptibility. by Ci Fu (148006)

    Published 2025
    “…Log rank (Mantel-Cox) test assessed significant difference between wild type and <i><i>rht1</i></i>Δ/Δ. …”
  14. 18974

    Attention reduces decision uncertainty under high cognitive demand. by Rahul Garg (3064578)

    Published 2025
    “…(L) Fraction of glomeruli with significant changes with cued-odor. Yellow: increased, dark grey: decreased, light grey: unchanged. …”
  15. 18975

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  16. 18976
  17. 18977

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  18. 18978

    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  19. 18979

    Genetic interaction between <i>Zrf1</i> and RISC components regulates ISC proliferation during midgut damage. by Joshua Shing Shun Li (22505522)

    Published 2025
    “…</b> Box plots show median, quartiles, and range. Statistical significance determined by Student’s t-test; ns = not significant, **p < 0.01, ****p < 0.0001.…”
  20. 18980

    Table 1_Expression and diagnostic values of ferroptosis-related genes in coronavirus-associated viral sepsis.xlsx by Yidan Zhang (130332)

    Published 2025
    “…Functional enrichment analyses using GO and KEGG revealed significant enrichment in signaling pathways related to ferroptosis, oxidative stress, and HIF-1. …”